What do hackers already know about your business? Get Your Free Report
Alleged

Eli Lilly and Company Data Breach

Published: Nov 16, 2026 N0n

Threat Level

High

Confidence: High

Quick Summary

Company
Eli Lilly and Company Data Breach
Industry
Healthcare
Threat Actor
N0n
Date of Incident
Nov 16, 2026

Executive Summary

Eli Lilly and Company — one of the world’s largest pharmaceutical corporations and the manufacturer of GLP-1 therapies including Mounjaro and Zepbound — has been listed as a claimed victim by the N0n ransomware group as of November 16, 2026. Eli Lilly operates globally with a workforce exceeding 40,000 employees, maintaining extensive research, manufacturing, and commercial operations across the United States and international markets. The company’s scale, its central role in supplying GLP-1 therapies experiencing unprecedented global demand, and the intellectual property associated with its drug development pipelines make it a potentially attractive target for ransomware and extortion activity. N0n has accumulated more than 300 victim claims over the past 60 days, targeting large-scale U.S.-based enterprises across financial services, healthcare, and retail. Prior claimed victims include Samsung Electronics, Gap Inc., VF Corporation, and Alo Yoga. The claim against Eli Lilly aligns closely with the group’s recent targeting pattern, which emphasizes major U.S.-based enterprises, and the healthcare and pharmaceutical sector falls directly within N0n’s most frequently targeted industries during this period.

Technical Analysis

Infostealer telemetry reveals a severe credential exposure profile for Eli Lilly. Ten records associated with employee identities were identified in stealer-log samples as INTERNAL_AUTH_EMPLOYEE (category A), indicating direct compromise of corporate credentials across internal systems, identity infrastructure, and administrative platforms. An additional three records show corporate-pattern usernames on third-party platforms (category C), consistent with workstation-level compromise capturing credentials across multiple services during routine employee activity. The combined exposure — ten category A records targeting identity and administrative infrastructure — represents a high-confidence pre-intrusion signal consistent with initial access methodologies documented ahead of enterprise ransomware deployments. Credentials harvested by infostealers are frequently traded or validated by initial access brokers before being used to establish corporate account access, including Microsoft 365, VPN, and remote-access portals, which can serve as a foundation for ransomware deployment. This does not confirm that N0n used these exact credentials or this access path, but the exposure of internal authentication credentials materially raises the risk that corporate access could already be in the hands of malicious actors. The absence of additional correlated records in other feeds would not rule out compromise, since credentials may exist under alternate corporate domains, personal email aliases, or feeds outside the queried dataset, or may have been used and rotated before indexing. The pharmaceutical sector carries compounding ransomware risk beyond the immediate intrusion: intellectual property associated with drug development pipelines, operational dependencies in manufacturing and supply chain, and regulatory obligations that amplify incident costs and timelines. For a company of Eli Lilly’s scale — particularly given its role supplying GLP-1 therapies experiencing unprecedented global demand — a confirmed intrusion affecting regulated data systems would trigger obligations under FDA oversight and 21 CFR Part 11 electronic records requirements. Security teams should immediately escalate investigation of identified accounts, enforce mandatory credential rotation across all systems accessible by implicated identities, and assess whether compromised credentials could have provided access to research data, clinical trial systems, or manufacturing control infrastructure during the period between credential exposure and the November 16 claim publication date. Continued dark web and stealer-log monitoring, proactive credential-hygiene checks, multi-factor authentication review, and monitoring of Microsoft 365, VPN, and remote-access activity are recommended.

Disclaimer

This report is intended for threat intelligence and security awareness purposes. SOCRadar does not host, redistribute or buy stolen data. All breach information reported here is collected from publicly accessible threat actor and ransomware portals. This content is intended to equip CTI teams with context around recent attacks. While we strive for accuracy, listings on ransomware leak and extortion sites cannot always be independently verified and may not reflect confirmed breaches. If you believe any data in this report is incorrect, please contact us.

Share

LinkedIn